INS19 CAR-T
/ Beijing Imunopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 17, 2024
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.
CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Leukemia • Oncology
1 to 1
Of
1
Go to page
1